Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents

American Journal of Therapeutics

Volumn 13, Issue 3, 2006, Pages 261-273

  Mosnaim, Aron D ^a   Ranade, Vasant V ^b   Wolf, Marion E ^c   Puente, Javier ^d   Antonieta Valenzuela, M ^d  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c International Neuropsychiatry Consultants   (United States)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Alzheimer; Aminopeptidase inhibitors; Antiarrhythmics; Antidepressants; Antiemetics; Antiepileptic; Antihistaminics; Cancer; Chemical structure pharmacologic activity: antipsychostics; Coronary vasodilators; Immunomodulators; Migraine; Phenothiazines; Sedatives

Indexed keywords

ACEPROMAZINE; ACEPROMETAZINE; ALIMEMAZINE; ANALGESIC AGENT; ANTHELMINTIC AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMIGRAINE AGENT; ANTIPRURITIC AGENT; ANTITUSSIVE AGENT; BUTAPERAZINE; CHLORPHENETHAZINE; CORONARY VASODILATING AGENT; CYAMEMAZINE; DIETHAZINE; ETACIZINE; LOCAL ANESTHETIC AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; PERAZINE; PHENOTHIAZINE; PROFENAMINE; RADIOPROTECTIVE AGENT; SEDATIVE AGENT; SPASMOLYTIC AGENT; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANESTHESIA; ANTIBACTERIAL ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CATALEPSY; CONSTIPATION; CREUTZFELDT JAKOB DISEASE; DISEASE EXACERBATION; DROWSINESS; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MULTIDRUG RESISTANCE; MUSCLE DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; X RAY CRYSTALLOGRAPHY; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; PHENOTHIAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745814747     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000212897.20458.63     Document Type: Review

References (40)

1. Bernthsen A. Inaugural-Dissertation: Di- und Triphenothiazine-Neue Modellsysteme für redoxschaltbare molekulare Drathe. Heidelberg University, Germany, 1883;1-252 (German patent 25 150).
2. Perez A. Medicina pintoresca: de los colorants artificiales a los primeros antipsicoticos. Available at: www.geocities.com/Athens/Parthenon/8584/ fenergan.htm, 2004.
3. Amaral L, Kristiansen JE, Viveiros M, et al. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrobial Ther. 2003;47:505-501.
4. Frankenburg FR. History of the development of antipsychotic medication. In: Romm S, Friedman RS, eds. The Psychiatric Clinics of North America. Philadelphia: WB Saunders Co; 1994, vol. 17:531-540.
5. Booth RG, Neumayer JL. Psychoterapeutic drugs: antipsychotic and anxiolytic agents. In: Williams DA, Lemke TL, eds. Foye's Principles of Medicinal Chemistry. New York: Lippincott Williams & Wilkins; 2002: 408-433.
6. Jarvik ME. In: Goodman LS, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. IV ed. New York: Macmillan Publishing Co; 1975.
7. Baldessarini RJ. In: Hardman JG, Limbird JG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. XI ed. New York: Macmillan Publishing Co; 2005.
8. Erhlich P. Chemotherapeutics: scientific principles, methods and results. Lancet ii. 1913;2:445-451.
9. Muller TJJ, Kramer CS. Synthesis of functionalized alkynylated phenothiazines, in Fourth International Electronic Conference on Synthetic Organic Chemistry (ECSOC-4), www.mdpi.org/ecsoc-4.htm, Abstract A0075, 2000.
10. The Lundbeck Institute (Denmark), ed. Psychotropics. Denmark, The Lund beck Institute, 2000.
11. Wes olowska O, Heindrich AB, Motohashi N, et al. Phenothiazine derivative causes phase separation in phosphatidylethanolamine model membranes Curr. Topics Biophys. 2001;25:71-73.
12. Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs: Investigational Drugs Journal. 2002;5:349-355.
13. Grembecka J, Kafarski P. Leucine aminopeptidase as a target for inhibitor design. Mini Rev Med Chem. 2001;1:133-144.
14. Mosnaim AD, Puente J, Saavedra R, et al. In vitro human plasma leucine-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. Pharmacology. 2003;67:6-13.
15. Wischick CM, Edwards PC, Lai RYK, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci. 1996;93:11213-11218.
16. Korth C, Barnaby CHM, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapics for prion disease. Proc Natl Acad Sci. 2001;98:9836-9841.
17. United States Pharmacopeia Dictionary of United States Adopted Names (USAN) and International Drug Names (40th ed; 2004). United States Pharmacopeial Convention, Inc, Rockville, MD;
18. The Merck Index (13th ed; 2001), Merck and Co. Inc, Whitehouse Station, NJ, USA.
19. Forrest IS, Carr CJ, Usdin E, eds. Phenothiazines and Structurally Related Drugs. New York: Raven Press; 1974.
20. Kaufman JJ, Koski WS. Physicochemical, quantum chemical, and other theoretical techniques for the understanding of the mechanism of action of CNS agents: psychoactive drugs, narcotics, and narcotic antagonists and anesthetics. In: Ariens EJ, ed. Drug Design. London, England: Academic Press; vol V, 1975:251-340.
21. Kuhn DM, Lovenberg W. Role of calmodulin in the activation of tryptophan hydroxylase. Fed Proceed. 1982;41:2258-2264.
22. Parameswaran VK, Seshadrinathan AG. In: Usdin E, Eckert H, Forrest IS, eds. The Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies. New York: Elsevier; 1980.
23. Joos R, Kyburz E. In: Usdin E, Eckert H, Forrest IS, eds. The Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies. New York: Elsevier; 1980: 37.
24. Dahl SG, Hough E, Hals PA. Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986;35:1263-1269.
25. Cole JO. Therapeutic efficacy of antidepressant drugs: a review. J Amer. Medical Assoc. 1964;124-275.
26. Jeding I, Evans PJ, Akamu D, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol. 1995;49:359-365.
27. Cook L, Weidley E. Behavioral effects of some psychopharmacological agents. Ann N Y Acad Sci. 1957;66:740-752.
28. Killam KF, Killam E. The action of lysergic acid diethylamide on central efferent and limbic pathways in the cat. J Pharmacol Exper Therapeutics. 1956;116:35-36.
29. Bolotina V, Courtney KR, Khodorov B. Gate-dependent blockade of sodium channels by phenothiazine derivatives: structure-activity relationships. Molecular Pharmacol. 1992;42:423-431.
30. Daniel WA. Mechanism of cellular distribution of psychotropic drugs. Significance for drug actions and interactions. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:65-73.
31. Baur EW. The structure-activity relationship of tricyclic amines. J Pharmacol Exper Therapeutics. 1971;177:219-226.
32. Niemegeers CJE. Antiemetic specificity of dopamine antagonists. Psychopharmacology. 1982;78:210-213.
33. Hille B. Local anesthetics. Hydrophilic and hydrophobic pathways for the drug receptor interactions. J Gen Physiology. 1977;69:497-515.
34. Courtney K. Review: quantitative structure activity relations based on use dependent and kinetics on myocardium. J Mol Cell Cardiology. 1987;19:319-330.
35. Usdin H, Eckert IS, Forrest CJ, eds. International Symposium: Phenothiazines and Structurally Related Drugs. Holland: Elsevier, Zurich, Switzerland; 1979.
36. Da Silva OA, Lopez M. Pipazethate - acute childhood poisoning. Clin Toxicol. 1977;11:455-458.
37. Molnar J, Mandi Y, Holland IB, et al. Antibacterial effect, plasmid curing activity and chemical structure of some tricyclic compounds. Acta Microbiol Acad Sci Hung. 1977;24:1-6.
38. Maurer H, Pfleger K. identification of phenothiazine antihistamines and their metabolites in urine. Arch Toxicol. 1988;62:185-191.
39. Mosnaim AD, Puente J, Hoang C, et al. Inhibition of human plasma leucine-enkephalin aminopeptidase hydrolysis by various endogenous peptides and a select number of clinically used drugs. Am J Therapeutics. 2004;11:459-466.
40. Wolf ME, Mosnaim AD, eds. Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington, DC: American Psychiatric Press; 1988.